title: Immunotherapy of cancer through targeting of the p53 tumor antigen.
abstract: The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or autoimmune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for the immunotherapy of cancer.
authors.affiliation: Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Tumor Immunology Group, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
authors.forename: Sander
authors.initials: S
authors.lastname: Zwaveling
authors.forename: Sjoerd H
authors.initials: SH
authors.lastname: Van der Burg
authors.forename: Anand G
authors.initials: AG
authors.lastname: Menon
authors.forename: Cornelis J M
authors.initials: CJ
authors.lastname: Melief
authors.forename: Rienk
authors.initials: R
authors.lastname: Offringa
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000378:metabolism*; D015551:Autoimmunity; D015179:Colorectal Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2